{"id":"https://openalex.org/W2589333318","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.7569","title":"Phase II randomized study of the safety, efficacy, metabolism, and molecular targets of erlotinib in African Americans (AA) with NSCLC.","display_name":"Phase II randomized study of the safety, efficacy, metabolism, and molecular targets of erlotinib in African Americans (AA) with NSCLC.","publication_year":2010,"publication_date":"2010-05-20","ids":{"openalex":"https://openalex.org/W2589333318","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.7569","mag":"2589333318"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2010.28.15_suppl.7569","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.7569","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.7569","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5015548619","display_name":"Miguel Angel Villalona-Calero","orcid":"https://orcid.org/0000-0002-1991-5070","observed_orcids":["https://orcid.org/0000-0002-1991-5070"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. A. Villalona-Calero","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014554706","display_name":"Thomas E. Stinchcombe","orcid":"https://orcid.org/0000-0002-3595-8011","observed_orcids":["https://orcid.org/0000-0002-3595-8011"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T. Stinchcombe","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066257150","display_name":"Mitch A. Phelps","orcid":"https://orcid.org/0000-0002-1615-5280","observed_orcids":["https://orcid.org/0000-0002-1615-5280"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. A. Phelps","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017420839","display_name":"S. L. Starrett","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. L. Starrett","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"A. C. Papp","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. C. Papp","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112238769","display_name":"A. M. Ghany","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. M. Ghany","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109333912","display_name":"William J. Hicks","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W. J. Hicks","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079014774","display_name":"Greg A. Otterson","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G. A. Otterson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078629724","display_name":"Mark A. Socinski","orcid":"https://orcid.org/0000-0003-2915-9325","observed_orcids":["https://orcid.org/0000-0003-2915-9325","https://orcid.org/0000-0002-8213-0137"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. A. Socinski","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5103090874","display_name":"Wenchen Zhao","orcid":"https://orcid.org/0000-0003-4450-6292","observed_orcids":["https://orcid.org/0000-0003-4450-6292"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W. Zhao","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"28","issue":"15_suppl","first_page":"7569","last_page":"7569"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9909999966621399},{"id":"https://openalex.org/keywords/african-americans","display_name":"African Americans","score":0.953000009059906},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7889999747276306},{"id":"https://openalex.org/keywords/pharmacogenetics","display_name":"pharmacogenetics","score":0.8560000061988831},{"id":"https://openalex.org/keywords/cyp3a4","display_name":"CYP3A4","score":0.8550000190734863},{"id":"https://openalex.org/keywords/cyp3a5","display_name":"CYP3A5","score":0.9700000286102295},{"id":"https://openalex.org/keywords/egfr-mutation","display_name":"EGFR mutation","score":0.7799999713897705},{"id":"https://openalex.org/keywords/egfr-amplification","display_name":"EGFR amplification","score":0.8640000224113464},{"id":"https://openalex.org/keywords/kras-mutation","display_name":"KRAS mutation","score":0.9309999942779541},{"id":"https://openalex.org/keywords/skin-rash","display_name":"rash","score":0.6029999852180481},{"id":"https://openalex.org/keywords/disease-control-rate","display_name":"disease control rate","score":0.9070000052452087},{"id":"https://openalex.org/keywords/drug-metabolism","display_name":"drug metabolism","score":0.35499998927116394},{"id":"https://openalex.org/keywords/molecular-targets","display_name":"molecular targets","score":0.3700000047683716},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.4350000023841858}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8746613264083862},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.6836622953414917},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.6577505469322205},{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.6478554010391235},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6084286570549011},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.544633686542511},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4749448597431183},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.45637238025665283},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.4366023540496826},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3975573778152466},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.38488054275512695},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2827569544315338},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.2148454785346985},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.18556323647499084}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2010.28.15_suppl.7569","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.7569","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.7569","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2080090381","https://openalex.org/W2591373827","https://openalex.org/W2121769645","https://openalex.org/W2248723952","https://openalex.org/W2623991075","https://openalex.org/W2530856523","https://openalex.org/W2288175449","https://openalex.org/W2067104291","https://openalex.org/W4234670855","https://openalex.org/W2589613430"],"abstract_inverted_index":{"7569":[0],"Background:":[1],"We":[2],"sought":[3],"to":[4,51,78,128,230,352,362],"characterize":[5],"clinical":[6],"outcomes,":[7],"EGFR/RAS":[8],"mutations,":[9],"EGFR":[10,238,263,292],"amplification,":[11],"pharmacokinetics":[12],"(PK)":[13],"and":[14,70,84,91,100,133,137,148,181,184,219,246,282,298,317,349],"pharmacogenetics":[15],"(PG)":[16],"in":[17,30,81,125,174,186,217,233,242,266,291,319],"AA":[18,320],"patients":[19],"receiving":[20],"erlotinib":[21,29],"for":[22,323,329],"previously":[23],"treated":[24],"NSCLC.":[25],"Methods:":[26],"Pts":[27],"received":[28],"a":[31,247],"phase":[32],"II":[33],"2-stage":[34],"minimax":[35],"randomized":[36],"study,":[37],"at":[38,66,97,122],"the":[39,162,307,333,364,367],"standard":[40],"150":[41],"mg":[42],"daily":[43],"(Arm":[44,55],"A),":[45],"or":[46,374,378],"escalated":[47],"after":[48],"1":[49,99,155,278,283],"cycle":[50],"achieve":[52],"skin":[53,159],"rash":[54,145,160,327,347],"B).":[56],"Primary":[57],"endpoint":[58],"was":[59,166,264],"disease":[60],"control":[61],"rate":[62],"(DCR,":[63],"RECIST":[64],"CR+PR+SD)":[65],"3":[67,123,274],"months.":[68],"PBMCs":[69],"tumor":[71,85],"tissue":[72],"were":[73,95,256,310],"collected":[74],"from":[75,88],"all":[76],"pts":[77,105,127,176,187,270],"identify":[79],"SNPs":[80,290,369],"metabolizing":[82],"enzymes,":[83],"mutations/amplification.":[86],"PKs":[87],"parent":[89,179],"drug":[90,180],"active":[92],"metabolite":[93,182],"(OSI-420)":[94],"evaluated":[96],"days":[98],"28.":[101],"Results:":[102],"Of":[103],"42":[104],"randomized,":[106],"39":[107],"(37":[108],"current/former":[109],"smokers)":[110],"started":[111],"erlotinib,":[112],"21":[113],"on":[114,118,161],"Arm":[115,119],"A,":[116],"18":[117],"B.":[120],"DCR":[121],"months":[124,165],"37":[126],"date":[129],"is":[130],"32%":[131],"(30":[132],"35%,":[134],"Arms":[135],"A":[136,355],"B,":[138],"respectively).":[139],"Grade":[140],"\u22653":[141],"adverse":[142],"events":[143],"included":[144],"(2":[146],"pts),":[147],"muscle":[149],"weakness,":[150],"dyspnea,":[151],"dehydration,":[152],"thrombosis,":[153],"anemia,":[154],"pt":[156],"each.":[157],"No":[158],"first":[163],"two":[164],"associated":[167],"with":[168,188,223,346],"early":[169],"PD":[170],"(10/11).":[171],"PK":[172,234],"analysis":[173],"26":[175],"showed":[177],"higher":[178],"Cmax":[183,199],"AUCs":[185],"grades":[189,192],"0-1":[190],"vs.":[191,205],"2-3":[193],"rashes":[194],"(cycle":[195],"2":[196],"OSI-420":[197],"mean":[198],"of":[200,306,326,366],"107":[201],"\u00b1":[202,207],"83":[203],"ng/mL":[204],"243":[206],"165":[208],"ng/mL,":[209],"respectively;":[210],"ANOVA":[211],"p-value":[212],"=":[213],"0.01).":[214],"SNP":[215],"presence":[216],"CYP3A4":[218],"CYP3A5":[220],"also":[221],"trends":[222],"PK,":[224],"but":[225,332],"not":[226,337],"statistically":[227],"significant":[228],"due":[229],"high":[231],"variability":[232],"parameter":[235],"estimates.":[236],"One":[237],"exon":[239,249,293],"19":[240],"short":[241],"frame":[243],"deletion":[244],"mutation":[245,255],"novel":[248],"20":[250,294],"missense":[251],"R776L":[252],"(c.2373":[253],"G>T)":[254],"identified":[257],"among":[258],"28":[259],"samples":[260],"already":[261],"analyzed.":[262],"amplified":[265],"9/20":[267],"samples.":[268],"5":[269],"had":[271],"Kras":[272,299],"mutations:":[273],"G12C":[275],"(c.32":[276],"G>T),":[277],"G12D":[279],"(c.33":[280,285],"G>A),":[281],"G12V":[284],"G>T).":[286],"Silent":[287],"mutations":[288],"indicating":[289],"Q787Q":[295],"(c.2470":[296],"G>A)":[297],"(-9,":[300],"C>T),":[301],"9":[302],"base":[303],"pairs":[304],"upstream":[305],"transcription":[308],"site,":[309],"noted.":[311],"Conclusions:":[312],"Erlotinib":[313],"has":[314],"similar":[315],"efficacy":[316],"toxicity":[318],"as":[321],"reported":[322],"caucasians.":[324],"Absence":[325],"predicted":[328],"worst":[330],"outcome,":[331],"dose-to-rash":[334],"strategy":[335],"did":[336],"show":[338],"meaningful":[339],"differences.":[340],"PKs,":[341],"although":[342],"highly":[343],"variable,":[344],"correlate":[345],"occurrence":[348],"may":[350],"relate":[351],"CYP":[353],"genotype.":[354],"larger":[356],"sample":[357],"size":[358],"will":[359],"be":[360],"required":[361],"evaluate":[363],"role":[365],"PBMC/tumor":[368],"identified.":[370],"Author":[371],"Disclosure":[372],"Employment":[373],"Leadership":[375],"Position":[376],"Consultant":[377],"Advisory":[379],"Role":[380],"Stock":[381],"Ownership":[382],"Honoraria":[383],"Research":[384],"Funding":[385],"Expert":[386],"Testimony":[387],"Other":[388],"Remuneration":[389],"Genentech":[390,391]},"counts_by_year":[{"year":2012,"cited_by_count":1}],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2017-03-03T00:00:00"}